LifeWise
Health Plan of Washington

ADMINISTRATIVE GUIDELINE – 10.01.530
Services Reviewed Using InterQual Criteria

Effective Date:	**Sept. 1, 2024***	RELATED MEDICAL POLICIES:
Last Revised:	Aug. 13, 2024	None
Replaces:	N/A	
*This policy has been revised. Click here to view the upcoming changes.		

Select a hyperlink below to be directed to that section.

ADMINISTRATIVE GUIDELINE | HISTORY

Clicking this icon returns you to the hyperlinks menu above.

Introduction

The Plan uses InterQual to review certain services for medical necessity as listed in this guideline. InterQual is evidence-based criteria that offers guidance in covering medical and behavioral health for all levels of care in addition to care planning, complex care management, durable medical equipment, procedures, and specialty pharmacy.

Note: The Introduction section is for your general knowledge and is not to be taken as policy coverage criteria. The rest of the policy uses specific words and concepts familiar to medical professionals. It is intended for providers. A provider can be a person, such as a doctor, nurse, psychologist, or dentist. A provider also can be a place where medical care is given, like a hospital, clinic, or lab. This policy informs them about when a service may be covered.

Administrative Guideline

Medical Necessity	
The following services are considered medically necessary when criteria are met using InterQual criteria:	
Module	**Service**

Medical Necessity	
Acute Adult	• Acute Kidney Injury • Anemia/Bleeding • Antepartum • Asthma • Capsule endoscopy • Capsule Endoscopy, Colon • Capsule Endoscopy, Small Bowel or Esophageal • Carbon Monoxide Poisoning • Cholecystitis • Chronic Obstructive Pulmonary Disease (COPD) • Cystic Fibrosis • Deep Vein Thrombosis • Diabetes Mellites (DM) • Diabetic Ketoacidosis (DKA) • Electrolyte/Mineral Imbalance • Epilepsy • Extended Stay • General Medical • General Trauma • Heart Failure • Hematology/Oncology: Acute Myeloid Leukemia • Hematology/Oncology: Brain Malignancy/Metastasis • Hematology/Oncology: Chemo • Hematology/Oncology: Hemolytic Uremic Syndrome • Hematology/Oncology: Malignant Disease • Hematology/Oncology: Tumor Lysis Syndrome • Hip arthrotomy • Hyperosmolar Hyperglycemic State • Hypertension • Hypertensive Disorder in Pregnancy • Hypoglycemia • Infection: Central Nervous System (CNS) • Infection: Endocarditis • Infection: General • Infection: Gastrointestinal/Genitourinary/Gynecology • Infection: Musculoskeletal • Infection: Pneumonia

Medical Necessity	
	• Infection: Sepsis • Infection: Skin • Irritable Bowel Disease • Labor & Delivery • Pancreatitis • Postpartum Complications After Discharge • Pulmonary Embolism • Quality Indicator Checklist • Rhabdomyolysis or Crush Syndrome • Sickle Cell Crisis • Stroke • Syncope • Total Joint Replacement (TJR) Ankle • Transient Ischemic Attack (TIA) • Transition Plan (Continued Stay and Transition Planning only) • Withdrawal Syndrome • Wound debridement
Acute Pediatrics	• Acetaminophen Overdose • Acute Kidney Injury • Anemia/Bleeding • Antepartum • Asthma • Brief Unresolved Unexplained Event • Bronchiolitis • Capsule Endoscopy (Pediatric) • Carbon Monoxide Poisoning • Cellulitis • Croup • Cystic Fibrosis • Dehydration/Gastroenteritis • Diabetic Ketoacidosis (DKA) • Diabetes Mellites (DM) • Electrolyte/Mineral Imbalance • Epilepsy • Extended Stay • Failure to Thrive

Medical Necessity	
	• General Medical • General Trauma • Hematology/Oncology: Chemotherapy • Hematology/Oncology: Acute Leukemia • Hematology/Oncology: Brain Malignancy/Metastasis • Hematology/Oncology: Hemolytic Uremic Syndrome • Hematology/Oncology: Malignant Disease • Hematology/Oncology: Tumor Lysis Syndrome • Hip Arthrotomy • Hyperbilirubinemia • Hypertensive Disorder in Pregnancy • Hypoglycemia • Infection: Central Nervous System (CNS) • Infection: Endocarditis • Infection: General • Infection: Gastrointestinal/Genitourinary/Gynecology • Infection: Meningitis • Infection: Musculoskeletal • Infection: Pneumonia • Infection: Pyelonephritis • Infection: Sepsis • Infection: Skin • Labor & Delivery • Nursery • Pancreatitis • Postpartum Complications After Discharge • Quality Indicator Checklist • Rhabdomyolysis or Crush Syndrome • Sickle Cell Crisis • Transition Plan (Continued Stay and Transition Planning only) • Withdrawal Syndrome • Wound Debridement
Behavioral Health	• Adult and Geriatric Psychiatry • Applied Behavior Analysis for Autism Spectrum Disorder • Child and Adolescent Psychiatry • Electroconvulsive Therapy: Adolescent

Medical Necessity	
	• Electroconvulsive Therapy: Adult/Geriatric • Neurobehavioral Status Exam • Neuropsychological Testing • Neuropsychological Testing: Pediatric • Pharmacogenomic Testing for Psychotropic Medication Drug Response • Psychological Testing • Stereotactic Introduction: Subcortical Electrodes • Substance Abuse Disorders
Durable Medical Equipment (DME)	• Home Oxygen Therapy • Negative Pressure Wound Therapy (NPWT) Pump • Orthosis, Spinal (Thoracolumbosacral)
Home Care	• Adult and Pediatric
Long Term Acute Care (LTAC)	• Medically Complex • Respiratory Complex • Transition Plan • Ventilator Weaning • Wound/Skin
Procedures	• Endovascular Repair, Abdominal Aortic Aneurysm (AAA) • Implantable Cardioverter Defibrillator (ICD Insertion) • Salpingo-Oophorectomy, Bilateral, Oophorectomy, Bilateral • Salpingo-Oophorectomy, Unilateral, Oophorectomy, Unilateral • Mastectomy, Prophylactic, Total or Simple
Rehabilitation	• Amputation, Lower Extremity Rehabilitation (Adult, Adolescent, School Age) • Amputation, Upper Extremity Rehabilitation (Adult, Adolescent, School Age) • Cardiac Rehabilitation (Adult) • Carpal Tunnel Syndrome Rehabilitation (Adult) • Cerebrovascular Accident Rehabilitation (Adult) • DeQuervain's Tenosynovitis Rehabilitation (Adult) • Fractures, Lower Extremity (Adult, Adolescent, School Age) • Fractures, Upper Extremity Rehabilitation (Adult, Adolescent, School Age) • General Deconditioning Rehabilitation (Adult)

Medical Necessity	
	• Habilitation (Adult, Adolescent, School Age) • Habilitation Criteria • Instability Dislocation Shoulder Rehabilitation (Adult) • Ligamentous Injury Ankle Rehabilitation (Adult, Adolescent, School Age) • Ligamentous Injury Knee Rehabilitation (Adult, Adolescent, School Age) • Lymphedema Rehabilitation (Adult) • Maintenance Therapy Rehabilitation (Adult) • Meniscal Injury Knee Rehabilitation (Adult, Adolescent, School Age) • Multiple Sclerosis Rehabilitation (Adult) • Osteoarthritis Hip Rehabilitation (Adult) • Osteoarthritis Rehabilitation, Knee (Adult) • Osteoarthritis Rehabilitation, Shoulder (Adult) • Pain Syndromes Rehabilitation (Adult, Adolescent) • Pediatric Rehabilitation Criteria • Pelvic Floor Rehabilitation • Pulmonary Rehabilitation (Adult) • Rotator Cuff Disorders Rehabilitation (Adult, Adolescent, School Age) • Soft Tissue Disorders Knee Rehabilitation (Adult, Adolescent, School Age) • Soft Tissue Disorders Rehabilitation, Foot and Ankle (Adult Adolescent, School Age) • Soft Tissue Disorders, Rehabilitation (Adult) • Spinal Disorders Rehabilitation, Cervical (Adult) • Spinal Disorders Rehabilitation, Lumbar (Adult, Adolescent, School Age) • Sprain Wrist Rehabilitation (Adult, Adolescent, School Age) • Strain Low Back Rehabilitation (Adult, Adolescent, School Age) • Strain Neck Rehabilitation (Adult, Adolescent, School Age) • Tendon Injury Hand Rehabilitation (Adult, Adolescent, School Age) • Tendon Rupture Achilles Rehabilitation (Adult)

Medical Necessity	
	• Thoracic Outlet Syndrome Rehabilitation (Adult, Adolescent, School Age) • Traumatic Brain Injury Rehabilitation (Adult) • Trigger Finger Rehabilitation (Adult) • Ulnar Neuropathy Rehabilitation (Adult, Adolescent, School Age)
Specialty Rx Non-Oncology	• Alpha 1 Proteinase Inhibitor • Bevacizumab Intravitreal • Factor Ix (Alphanine Sd) • Factor Ix (Bebulin Vh, Profilnine Sd) • Factor Ix (Benefix, Rixubis) • Factor Viii (Advate) • Factor Viii (Alphanate) • Factor Viii (Hemofil M) • Factor Viii (Humate-P) • Factor Viii (Wilate) • Factor Viii (Xyntha) • Factor Viii or Ix (Feiba Nf) • Factor Xiii (Corifact) • Hydroxyprogesterone Caproate • Lanreotide • Octreotide Acetate (Sandostatin Lar Depot) • Octreotide Acetate (Sandostatin) • Rho(D) Immune Globulin (Rhophylac) • Rho(D) Immune Globulin (Winrho)
Specialty Rx Oncology	• Plerixafor • Rolapitant Injection • Zoledronic Acid
Subacute/Skilled Nursing Facility	• Maintenance Therapy

History

Date	Comments
09/16/19	New administrative guideline, approved August 30, 2019, effective January 1, 2020, developed to aid in navigation to InterQual clinical criteria for use in the individual market.
10/22/19	Minor update, the policy was corrected to remove drugs that will not be addressed using InterQual criteria. These had been added in error.
11/21/19	Interim Review, approved November 12, 2019, effective February 21, 2020. Added rehabilitative services to be reviewed using InterQual as listed; considered medically necessary when criteria are met.
12/01/19	Minor update, the policy was corrected to remove additional drugs that will not be addressed using InterQual criteria. These had been added in error.
04/01/20	Interim Review, approved March 10, 2020. The following changes are effective July 2, 2020, following provider notification. Services within durable medical equipment and procedures were added to those reviewed for medical necessity using InterQual criteria for dates of service July 2, 2020, and after. The following policies are no longer effective after that date: 1.01.10, 1.01.11, 1.01.15, 1.01.18, 1.01.30, 1.01.501, 1.01.519, 1.01.520, 1.01.527, 1.03.501, 2.01.40, 2.01.505, 2.01.533, 2.02.09, 2.02.26, 2.02.30, 2.02.506, 2.02.507, 6.01.25, 7.01.05, 7.01.07, 7.01.20, 7.01.107, 7.01.108, 7.01.109, 7.01.132, 7.01.138, 7.01.143, 7.01.503, 7.01.508, 7.01.516, 7.01.519, 7.01.521, 7.01.522, 7.01.523, 7.01.533, 7.01.542, 7.01.546, 7.01.549, 7.01.550, 7.01.551, 7.01.554, 7.01.555, 7.01.558, 7.01.560, 7.01.570, 7.01.573, 7.01.63, 7.01.84, 7.01.87, 7.01.95, 7.03.01, 7.03.09, 7.03.11, 7.03.509, 8.01.11, 8.01.15, 8.01.17, 8.01.21, 8.01.22, 8.01.29, 8.01.30, 8.01.36, 8.01.521, 9.03.01.
05/06/20	Interim Review, approved May 5, 2020. Corrections made: Policies 2.02.09, 7.01.07, 7.01.87, 7.01.95, 7.01.554, 7.03.09, 7.03.11 and 9.03.01 along with corresponding InterQual subsets removed; policies 8.01.529 and 8.01.532 added (subsets were listed but titles were inadvertently not included in reference policies). Autologous stem cell transplant subset added; it was left out in error.
06/09/20	Interim Review, approved June 9, 2020. Correction made policies 2.01.40, 2.01.505, 6.01.25, 7.01.107, 7.01.108, 7.01.109, 7.01.138, 7.01.508, 7.01.516, 7.01.522, 7.01.533, 7.01.542, 7.01.551, 7.01.555, 7.01.560, 7.01.570, 7.03.01, 7.03.509, 8.01.11, 8.01.15, 8.01.17, 8.01.21, 8.01.22, 8.01.29, 8.01.30, 8.01.521, 8.01.529, 8.01.532 along with corresponding InterQual subsets removed.
06/25/20	Interim Review, approved June 25, 2020. Removed policy 2.02.30 – this policy will remain active and InterQual will not replace this review criteria on July 2, 2020.
11/01/20	Annual Review, approved Oct. 13, 2020. Policy updated to remove outpatient procedures and DME which will no longer be in effect as of Feb. 5, 2021, pursuant to provider notification.
06/01/21	Interim Review, approved May 20, 2021. Removed aflibercept, ranibizumab, and reslizumab from Specialty Rx Non-Oncology.
08/01/21	Annual Review, approved July 9, 2021. Policy reviewed; no changes.

Date	Comments
09/01/22	Interim Review, approved August 9, 2022. Removed botulinum toxins from Pharmacy Specialty Rx Non-Oncology section. These drugs will now be reviewed with policy 5.01.512 Botulinum Toxins effective December 1, 2022.
10/01/22	Annual Review, approved September 26, 2022. Added Negative Pressure Wound Therapy to the DME section; added Capsule Endoscopy to acute Adult and Pediatric Acute sections replacing policies 1.01.532 Negative Pressure Wound therapy and 2.01.538 Capsule Endoscopy. Added Total Ankle Replacement to Adult Acute section to replace policy 7.01.577 Total Ankle Replacement; and added Electroconvulsive Therapy, both effective January 6, 2023 following 90-day provider notification.
01/01/23	Interim Review, approved December 13, 2022. Added Cardiac Defibrillator, Subcutaneous Implantable, Home Oxygen Therapy, and Spinal Orthosis to the list of services reviewed using InterQual criteria.
08/01/23	Annual Review, approved July 11, 2023. Added Endovascular Repair, Abdominal Aortic Aneurysm (AAA) and Mastectomy, Prophylactic, Total or Simple to the list of services reviewed using InterQual criteria to replace policies 2.02.513 Endovascular Repair-Stent for Abdominal Aortic Aneurysm and 7.01.581 Prophylactic Mastectomy.
09/01/23	Interim Review, approved August 8, 2023. Added Digital Breast Tomosynthesis to the list of services reviewed using InterQual criteria to replace policy 6.01.526 Digital Breast Tomosynthesis effective December 7, 2023 following 90-day provider notification.
12/07/23	Minor corrections. Corrected module listed under Imaging to, "Imaging, Breast" which replaced policy 6.01.526, Digital Breast Tomosynthesis" (incorrectly listed as "Digital Breast Tomosynthesis"). Also, corrected module name for Spinal Stenosis to "Orthosis, Spinal (Thoracolumbosacral)." Moved "Cardiac Defibrillator, Subcutaneous Implantable" from the Adult Acute section to the Procedures section and correctly listed as, "Implantable Cardioverter Defibrillator (ICD Insertion)."
01/01/24	Interim Review, approved December 12, 2023. Added salpingo-oophorectomy, bilateral and unilateral; and salpingo, unilateral and bilateral, to the Procedures section replacing policy 7.01.580, Prophylactic Bilateral Salpingo-Oophorectomy as of January 1, 2024.
09/01/24	Annual Review, approved August 13, 2024. Removed imaging, breast, as these services are not reviewed effective September 1, 2024.

Scope: Medical policies are systematically developed guidelines that serve as a resource for Company staff when determining coverage for specific medical procedures, drugs or devices. Coverage for medical services is subject to the limits and conditions of the member benefit plan. Members and their providers should consult the member benefit booklet or contact a customer service representative to determine whether there are any benefit limitations applicable to this service or supply. This medical policy only applies to Individual plans.

LifeWise

Discrimination is Against the Law

LifeWise Health Plan of Washington (LifeWise) complies with applicable Federal and Washington state civil rights laws and does not discriminate on the basis of race, color, national origin, age, disability, sex, gender identity, or sexual orientation. LifeWise does not exclude people or treat them differently because of race, color, national origin, age, disability, sex, gender identity, or sexual orientation. LifeWise provides free aids and services to people with disabilities to communicate effectively with us, such as qualified sign language interpreters and written information in other formats (large print, audio, accessible electronic formats, other formats). LifeWise provides free language services to people whose primary language is not English, such as qualified interpreters and information written in other languages. If you need these services, contact the Civil Rights Coordinator. If you believe that LifeWise has failed to provide these services or discriminated in another way on the basis of race, color, national origin, age, disability, sex, gender identity, or sexual orientation, you can file a grievance with: Civil Rights Coordinator ─ Complaints and Appeals, PO Box 91102, Seattle, WA 98111, Toll free: 855-332-6396, Fax: 425-918-5592, TTY: 711, Email AppealsDepartmentInquiries@LifeWiseHealth.com. You can file a grievance in person or by mail, fax, or email. If you need help filing a grievance, the Civil Rights Coordinator is available to help you. You can also file a civil rights complaint with the U.S. Department of Health and Human Services, Office for Civil Rights, electronically through the Office for Civil Rights Complaint Portal, available at https://ocrportal.hhs.gov/ocr/portal/lobby.jsf, or by mail or phone at: U.S. Department of Health and Human Services, 200 Independence Ave SW, Room 509F, HHH Building, Washington, D.C. 20201, 1-800-368-1019, 800-537-7697 (TDD). Complaint forms are available at http://www.hhs.gov/ocr/office/file/index.html. You can also file a civil rights complaint with the Washington State Office of the Insurance Commissioner, electronically through the Office of the Insurance Commissioner Complaint Portal available at https://www.insurance.wa.gov/file-complaint-or-check-your-complaint-status, or by phone at 800-562-6900, 360-586-0241 (TDD). Complaint forms are available at https://fortress.wa.gov/oic/onlineservices/cc/pub/complaintinformation.aspx.

Language Assistance

ATENCIÓN: si habla español, tiene a su disposición servicios gratuitos de asistencia lingüística. Llame al 800-817-3056 (TTY: 711).

注意：如果您使用繁體中文，您可以免費獲得語言援助服務。請致電 800-817-3056（TTY：711）。

CHÚ Ý: Nếu bạn nói Tiếng Việt, có các dịch vụ hỗ trợ ngôn ngữ miễn phí dành cho bạn. Gọi số 800-817-3056 (TTY: 711).

주의: 한국어를 사용하시는 경우, 언어 지원 서비스를 무료로 이용하실 수 있습니다. 800-817-3056 (TTY: 711) 번으로 전화해 주십시오.

ВНИМАНИЕ: Если вы говорите на русском языке, то вам доступны бесплатные услуги перевода. Звоните 800-817-3056 (телетайп: 711).

PAUNAWA: Kung nagsasalita ka ng Tagalog, maaari kang gumamit ng mga serbisyo ng tulong sa wika nang walang bayad. Tumawag sa 800-817-3056 (TTY: 711).

УВАГА! Якщо ви розмовляєте українською мовою, ви можете звернутися до безкоштовної служби мовної підтримки.
Телефонуйте за номером 800-817-3056 (телетайп: 711).

ប្រយ័ត្ន៖ បើសិនជាអ្នកនិយាយ ភាសាខ្មែរ, សេវាជំនួយផ្នែកភាសា ដោយមិនគិតឈ្នួល គឺអាចមានសំរាប់បំរើអ្នក។ ចូរ ទូរស័ព្ទ 800-817-3056 (TTY: 711)។

注意事項：日本語を話される場合、無料の言語支援をご利用いただけます。800-817-3056（TTY:711）まで、お電話にてご連絡ください。

ማስታወሻ: የሚናገሩት ቋንቋ አማርኛ ከሆነ የትርጉም እርዳታ ድርጅቶች፣ በነጻ ሊያግዝዎት ተዘጋጀተዋል፡ ወደ ሚከተለው ቁጥር ይደውሉ 800-817-3056 (መስማት ለተሳናቸው: 711).

XIYYEEFFANNAA: Afaan dubbattu Oroomiffa, tajaajila gargaarsa afaanii, kanfaltiidhaan ala, ni argama. Bilbilaa 800-817-3056 (TTY: 711).

ملحوظة: إذا كنت تتحدث اذكر اللغة، فإن خدمات المساعدة اللغوية تتوافر لك بالمجان. اتصل برقم 800-817-3056 (رقم هاتف الصم والبكم: 711).

ਧਿਆਨ ਦਿਓ: ਜੇ ਤੁਸੀਂ ਪੰਜਾਬੀ ਬੋਲਦੇ ਹੋ, ਤਾਂ ਭਾਸ਼ਾ ਵਿੱਚ ਸਹਾਇਤਾ ਸੇਵਾ ਤੁਹਾਡੇ ਲਈ ਮੁਫਤ ਉਪਲਬਧ ਹੈ। 800-817-3056 (TTY: 711) 'ਤੇ ਕਾਲ ਕਰੋ।

ACHTUNG: Wenn Sie Deutsch sprechen, stehen Ihnen kostenlos sprachliche Hilfsdienstleistungen zur Verfügung. Rufnummer: 800-817-3056 (TTY: 711).

ໂປດຊາບ: ຖ້າວ່າ ທ່ານເວົ້າພາສາ ລາວ, ການບໍລິການຊ່ວຍເຫຼືອດ້ານພາສາ, ໂດຍບໍ່ເສັງຄ່າ, ແມ່ນມີພ້ອມໃຫ້ທ່ານ. ໂທຣ 800-817-3056 (TTY: 711).

ATANSYON: Si w pale Kreyòl Ayisyen, gen sèvis èd pou lang ki disponib gratis pou ou. Rele 800-817-3056 (TTY: 711).

ATTENTION : Si vous parlez français, des services d'aide linguistique vous sont proposés gratuitement. Appelez le 800-817-3056 (ATS : 711).

UWAGA: Jeżeli mówisz po polsku, możesz skorzystać z bezpłatnej pomocy językowej. Zadzwoń pod numer 800-817-3056 (TTY: 711).

ATENÇÃO: Se fala português, encontram-se disponíveis serviços linguísticos, grátis. Ligue para 800-817-3056 (TTY: 711).

ATTENZIONE: In caso la lingua parlata sia l'italiano, sono disponibili servizi di assistenza linguistica gratuiti. Chiamare il numero 800-817-3056 (TTY: 711).

توجه: اگر به زبان فارسی گفتگو می کنید، تسهیلات زبانی بصورت رایگان برای شما فراهم می باشد. با 800-817-3056 (TTY: 711) تماس بگیرید.